Processa Pharmaceuticals, Inc. Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue
Processa Pharmaceuticals, Inc. (PCSA) reported Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue of $28.87 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-09-25.
Discontinued › Income Statement › Other Income
us-gaap:DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalRevenue · last filed 2017-09-25
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue for the quarter ending 2015-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue for the quarter ending 2015-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue for the quarter ending 2015-06-30 was $20.04K.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue for the quarter ending 2015-03-31 was $8.83K.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue for fiscal 2015 was $28.87K, a 68.94% decline from fiscal 2014.
- Processa Pharmaceuticals, Inc. discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue for fiscal 2014 was $92.96K.
| Period end | Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue 3 month | Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue 6 month | Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue 9 month | Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $0.00 derived: sum of 2 quarters · filed 2017-09-25 | $20.04K derived: sum of 3 quarters · filed 2017-09-25 | $28.87K 10-K · filed 2017-09-25 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | $20.04K derived: sum of 2 quarters · filed 2017-09-08 | $28.87K 10-Q · filed 2017-09-08 | |
| 2015-06-30 | $20.04K 10-Q · filed 2017-08-30 | $28.87K 10-Q · filed 2017-08-30 | ||
| 2015-03-31 | $8.83K 10-Q · filed 2017-08-07 | |||
| 2014-12-31 | $92.96K 10-K · filed 2017-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |